Benefits and unintended consequences of antimicrobial de-escalation: Implications for stewardship programs

Josie Hughes, Xi Huo, Lindsey Falk, Amy Hurford, Kunquan Lan, Bryan Coburn, Andrew Morris, Jianhong Wu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sequential antimicrobial de-escalation aims to minimize resistance to high-value broadspectrum empiric antimicrobials by switching to alternative drugs when testing confirms susceptibility. Though widely practiced, the effects de-escalation are not well understood. Definitions of interventions and outcomes differ among studies. We use mathematical models of the transmission and evolution of Pseudomonas aeruginosa in an intensive care unit to assess the effect of de-escalation on a broad range of outcomes, and clarify expectations. In these models, de-escalation reduces the use of high-value drugs and preserves the effectiveness of empiric therapy, while also selecting for multidrug-resistant strains and leaving patients vulnerable to colonization and superinfection. The net effect of de-escalation in our models is to increase infection prevalence while also increasing the probability of effective treatment. Changes in mortality are small, and can be either positive or negative. The clinical significance of small changes in outcomes such as infection prevalence and death may exceed more easily detectable changes in drug use and resistance. Integrating harms and benefits into ranked outcomes for each patient may provide a way forward in the analysis of these tradeoffs. Our models provide a conceptual framework for the collection and interpretation of evidence needed to inform antimicrobial stewardship.

Original languageEnglish (US)
Article numbere0171218
JournalPLoS One
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

anti-infective agents
drugs
Superinfection
Infection
Drug Resistance
Pharmaceutical Preparations
Pseudomonas aeruginosa
Intensive Care Units
Intensive care units
Theoretical Models
infection
preserves
Mortality
mathematical models
Therapeutics
Mathematical models
death
therapeutics
Testing
testing

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Benefits and unintended consequences of antimicrobial de-escalation : Implications for stewardship programs. / Hughes, Josie; Huo, Xi; Falk, Lindsey; Hurford, Amy; Lan, Kunquan; Coburn, Bryan; Morris, Andrew; Wu, Jianhong.

In: PLoS One, Vol. 12, No. 2, e0171218, 01.02.2017.

Research output: Contribution to journalArticle

Hughes, Josie ; Huo, Xi ; Falk, Lindsey ; Hurford, Amy ; Lan, Kunquan ; Coburn, Bryan ; Morris, Andrew ; Wu, Jianhong. / Benefits and unintended consequences of antimicrobial de-escalation : Implications for stewardship programs. In: PLoS One. 2017 ; Vol. 12, No. 2.
@article{c99413bc392b44bcabfbd5b1e604c99d,
title = "Benefits and unintended consequences of antimicrobial de-escalation: Implications for stewardship programs",
abstract = "Sequential antimicrobial de-escalation aims to minimize resistance to high-value broadspectrum empiric antimicrobials by switching to alternative drugs when testing confirms susceptibility. Though widely practiced, the effects de-escalation are not well understood. Definitions of interventions and outcomes differ among studies. We use mathematical models of the transmission and evolution of Pseudomonas aeruginosa in an intensive care unit to assess the effect of de-escalation on a broad range of outcomes, and clarify expectations. In these models, de-escalation reduces the use of high-value drugs and preserves the effectiveness of empiric therapy, while also selecting for multidrug-resistant strains and leaving patients vulnerable to colonization and superinfection. The net effect of de-escalation in our models is to increase infection prevalence while also increasing the probability of effective treatment. Changes in mortality are small, and can be either positive or negative. The clinical significance of small changes in outcomes such as infection prevalence and death may exceed more easily detectable changes in drug use and resistance. Integrating harms and benefits into ranked outcomes for each patient may provide a way forward in the analysis of these tradeoffs. Our models provide a conceptual framework for the collection and interpretation of evidence needed to inform antimicrobial stewardship.",
author = "Josie Hughes and Xi Huo and Lindsey Falk and Amy Hurford and Kunquan Lan and Bryan Coburn and Andrew Morris and Jianhong Wu",
year = "2017",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0171218",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Benefits and unintended consequences of antimicrobial de-escalation

T2 - Implications for stewardship programs

AU - Hughes, Josie

AU - Huo, Xi

AU - Falk, Lindsey

AU - Hurford, Amy

AU - Lan, Kunquan

AU - Coburn, Bryan

AU - Morris, Andrew

AU - Wu, Jianhong

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Sequential antimicrobial de-escalation aims to minimize resistance to high-value broadspectrum empiric antimicrobials by switching to alternative drugs when testing confirms susceptibility. Though widely practiced, the effects de-escalation are not well understood. Definitions of interventions and outcomes differ among studies. We use mathematical models of the transmission and evolution of Pseudomonas aeruginosa in an intensive care unit to assess the effect of de-escalation on a broad range of outcomes, and clarify expectations. In these models, de-escalation reduces the use of high-value drugs and preserves the effectiveness of empiric therapy, while also selecting for multidrug-resistant strains and leaving patients vulnerable to colonization and superinfection. The net effect of de-escalation in our models is to increase infection prevalence while also increasing the probability of effective treatment. Changes in mortality are small, and can be either positive or negative. The clinical significance of small changes in outcomes such as infection prevalence and death may exceed more easily detectable changes in drug use and resistance. Integrating harms and benefits into ranked outcomes for each patient may provide a way forward in the analysis of these tradeoffs. Our models provide a conceptual framework for the collection and interpretation of evidence needed to inform antimicrobial stewardship.

AB - Sequential antimicrobial de-escalation aims to minimize resistance to high-value broadspectrum empiric antimicrobials by switching to alternative drugs when testing confirms susceptibility. Though widely practiced, the effects de-escalation are not well understood. Definitions of interventions and outcomes differ among studies. We use mathematical models of the transmission and evolution of Pseudomonas aeruginosa in an intensive care unit to assess the effect of de-escalation on a broad range of outcomes, and clarify expectations. In these models, de-escalation reduces the use of high-value drugs and preserves the effectiveness of empiric therapy, while also selecting for multidrug-resistant strains and leaving patients vulnerable to colonization and superinfection. The net effect of de-escalation in our models is to increase infection prevalence while also increasing the probability of effective treatment. Changes in mortality are small, and can be either positive or negative. The clinical significance of small changes in outcomes such as infection prevalence and death may exceed more easily detectable changes in drug use and resistance. Integrating harms and benefits into ranked outcomes for each patient may provide a way forward in the analysis of these tradeoffs. Our models provide a conceptual framework for the collection and interpretation of evidence needed to inform antimicrobial stewardship.

UR - http://www.scopus.com/inward/record.url?scp=85012037105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012037105&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0171218

DO - 10.1371/journal.pone.0171218

M3 - Article

C2 - 28182774

AN - SCOPUS:85012037105

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0171218

ER -